These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29753836)

  • 21. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
    Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
    Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
    Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
    Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.
    Fishman JA; Doran MT; Volpicelli SA; Cosimi AB; Flood JG; Rubin RH
    Transplantation; 2000 Feb; 69(3):389-94. PubMed ID: 10706048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ; Busuttil RW
    Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.
    Kletzmayr J; Kreuzwieser E; Watkins-Riedel T; Berlakovich G; Kovarik J; Klauser R
    Transplantation; 2000 Oct; 70(8):1174-80. PubMed ID: 11063336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
    Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
    Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
    Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
    Goodrich JM; Mori M; Gleaves CA; Du Mond C; Cays M; Ebeling DF; Buhles WC; DeArmond B; Meyers JD
    N Engl J Med; 1991 Dec; 325(23):1601-7. PubMed ID: 1658652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
    Mandanas RA; Saez RA; Selby GB; Confer DL
    Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir.
    Brumble LM; Milstone AP; Loyd JE; Ely EW; Pierson RN; Gautam S; Dummer JS
    Chest; 2002 Feb; 121(2):407-14. PubMed ID: 11834650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Merigan TC; Renlund DG; Keay S; Bristow MR; Starnes V; O'Connell JB; Resta S; Dunn D; Gamberg P; Ratkovec RM
    N Engl J Med; 1992 Apr; 326(18):1182-6. PubMed ID: 1313549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.